Compare with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs PFIZER - Comparison Results

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES PFIZER ALKEM LABORATORIES/
PFIZER
 
P/E (TTM) x - 35.7 - View Chart
P/BV x 7.9 6.1 130.0% View Chart
Dividend Yield % 0.5 0.6 97.5%  

Financials

 ALKEM LABORATORIES   PFIZER
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
PFIZER
Mar-19
ALKEM LABORATORIES/
PFIZER
5-Yr Chart
Click to enlarge
High Rs1,5893,840 41.4%   
Low Rs1,2322,080 59.2%   
Sales per share (Unadj.) Rs417.5455.0 91.8%  
Earnings per share (Unadj.) Rs56.393.8 60.0%  
Cash flow per share (Unadj.) Rs64.7109.4 59.2%  
Dividends per share (Unadj.) Rs12.7022.50 56.4%  
Dividend yield (eoy) %0.90.8 118.5%  
Book value per share (Unadj.) Rs292.9658.2 44.5%  
Shares outstanding (eoy) m119.5745.75 261.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.46.5 51.9%   
Avg P/E ratio x25.131.6 79.4%  
P/CF ratio (eoy) x21.827.1 80.6%  
Price / Book Value ratio x4.84.5 107.1%  
Dividend payout %22.624.0 94.0%   
Avg Mkt Cap Rs m168,653135,420 124.5%   
No. of employees `000NA2.6 0.0%   
Total wages/salary Rs m9,1713,238 283.2%   
Avg. sales/employee Rs ThNM7,911.4-  
Avg. wages/employee Rs ThNM1,230.9-  
Avg. net profit/employee Rs ThNM1,630.7-  
INCOME DATA
Net Sales Rs m49,91520,815 239.8%  
Other income Rs m1,6451,674 98.3%   
Total revenues Rs m51,56122,489 229.3%   
Gross profit Rs m8,4825,712 148.5%  
Depreciation Rs m1,006714 140.9%   
Interest Rs m67173 919.9%   
Profit before tax Rs m8,4516,599 128.1%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6062,309 69.6%   
Profit after tax Rs m6,7314,291 156.9%  
Gross profit margin %17.027.4 61.9%  
Effective tax rate %19.035.0 54.3%   
Net profit margin %13.520.6 65.4%  
BALANCE SHEET DATA
Current assets Rs m27,06227,167 99.6%   
Current liabilities Rs m15,3248,917 171.8%   
Net working cap to sales %23.587.7 26.8%  
Current ratio x1.83.0 58.0%  
Inventory Days Days6768 98.1%  
Debtors Days Days4130 137.1%  
Net fixed assets Rs m12,6108,862 142.3%   
Share capital Rs m239458 52.3%   
"Free" reserves Rs m34,49029,656 116.3%   
Net worth Rs m35,02730,113 116.3%   
Long term debt Rs m1,21225 4,846.4%   
Total assets Rs m54,38739,400 138.0%  
Interest coverage x13.691.5 14.9%   
Debt to equity ratio x00 4,166.6%  
Sales to assets ratio x0.90.5 173.7%   
Return on assets %13.611.1 122.9%  
Return on equity %19.214.2 134.9%  
Return on capital %24.922.1 112.3%  
Exports to sales %12.90-   
Imports to sales %3.10-   
Exports (fob) Rs m6,461NA-   
Imports (cif) Rs m1,540NA-   
Fx inflow Rs m6,563428 1,532.4%   
Fx outflow Rs m3,012786 383.0%   
Net fx Rs m3,552-358 -991.8%   
CASH FLOW
From Operations Rs m7,259978 742.1%  
From Investments Rs m1,864351 530.8%  
From Financial Activity Rs m-9,273-1,099 844.1%  
Net Cashflow Rs m-150231 -65.0%  

Share Holding

Indian Promoters % 66.9 0.0 -  
Foreign collaborators % 0.0 63.9 -  
Indian inst/Mut Fund % 33.1 7.5 441.3%  
FIIs % 0.0 4.9 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 23.7 -  
Shareholders   68,381 85,207 80.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   IPCA LABS  GSK PHARMA  PANACEA BIOTECH  PROCTER & GAMBLE HEALTH  NOVARTIS  

Compare ALKEM LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Zooms 1,028 Points; Oil & Gas, FMCG and Metal Stocks Rally(Closing)

Indian share markets continued to trade in the green during closing hours and ended their day on a strong note, tracking global cues.

Related Views on News

PFIZER Announces Quarterly Results (3QFY20); Net Profit Up 5.4% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, PFIZER has posted a net profit of Rs 1 bn (up 5.4% YoY). Sales on the other hand came in at Rs 5 bn (up 4.7% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (2QFY20); Net Profit Up 61.0% (Quarterly Result Update)

Oct 29, 2019 | Updated on Oct 29, 2019

For the quarter ended September 2019, PFIZER has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 6 bn (up 9.1% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (1QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PFIZER has posted a net profit of Rs 1 bn (up 22.8% YoY). Sales on the other hand came in at Rs 5 bn (up 6.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (4QFY19); Net Profit Up 4.7% (Quarterly Result Update)

May 29, 2019 | Updated on May 29, 2019

For the quarter ended March 2019, PFIZER has posted a net profit of Rs 1 bn (up 4.7% YoY). Sales on the other hand came in at Rs 5 bn (up 3.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (3QFY19); Net Profit Up 51.2% (Quarterly Result Update)

Jan 25, 2019 | Updated on Jan 25, 2019

For the quarter ended December 2018, PFIZER has posted a net profit of Rs 1 bn (up 51.2% YoY). Sales on the other hand came in at Rs 5 bn (up 12.5% YoY). Read on for a complete analysis of PFIZER's quarterly results.

More Views on News

Most Popular

If I Were to Recommend One Stock Amid Coronavirus Outbreak, This Would be It.(Profit Hunter)

Mar 19, 2020

Coronavirus outbreak has made no impact on the long term prospects of my favourite smallcap. What it has indeed done is brought the company below my buy price, making it even more attractive investment at current price.

Why India Will Be the Biggest Winner in a Post-Coronavirus World(The 5 Minute Wrapup)

Mar 19, 2020

The way businesses operate will change in a major way post the coronavirus impact. Here's why India stands to benefit from this change...

A Big Trading Opportunity is Coming Your Way Soon(Fast Profits Daily)

Mar 25, 2020

I see a big opportunity to make fast profits on the horizon.

Coronavirus Sell-off Is a Perfect Time to 'Lockdown' this 'Crorepati' Stock(Profit Hunter)

Mar 24, 2020

Coronavirus crisis and panic selling has brought this quality smallcap to multiyear lows, making it a great bargain.

The Biggest Trading Opportunity of 2020 is Here...

Mar 26, 2020

India's #1 trader, Vijay Bhambwani, talks about a hugely profitable trading opportunity which you must know about today!

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Mar 31, 2020 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 8-QTR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS